Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00438906 · ClinicalTrials.gov registry record
Cancer of the Pancreas Screening Study (CAPS 3)
A clinical trial, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 200
- Enrollment target
NCT00438906: Completed study, sponsored by Johns Hopkins University.
NCT00438906 is a clinical trial that has completed, run by Johns Hopkins University. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00438906 has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to find the best and most sensitive screening modality (CT, MRI, EUS)for very small pre-cancerous pancreatic lesions and to treat these small lesions before they turn into cancer. Another purpose of this study is to search for common markers on DNA that would increase the chance of someone developing pancreatic cancer, and locate proteins in pancreatic juice that indicate tumor development.
Interventions
- DRUG Secretin (human synthetic) - ChiRhoClin
- PROCEDURE Biopsy, Fine Needle Aspiration (FNA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00438906
The ClinicalTrials.gov registry entry for NCT00438906 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Secretin (human synthetic) - ChiRhoClin is the first listed.
NCT00438906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00438906 about?
NCT00438906 is a clinical study titled "Cancer of the Pancreas Screening Study (CAPS 3)". The purpose of this study is to find the best and most sensitive screening modality (CT, MRI, EUS)for very small pre-cancerous pancreatic lesions and to treat these small lesions before they turn into cancer. Another purpose of this study is to search for common markers on DNA that would increase th...
What is the current status of trial NCT00438906?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2006-12. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00438906?
The interventions under investigation include: Secretin (human synthetic) - ChiRhoClin (DRUG), Biopsy, Fine Needle Aspiration (FNA) (PROCEDURE).
Who is sponsoring clinical trial NCT00438906?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.